A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Combination With Paclitaxel and Carboplatin in Subjects With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2017
At a glance
- Drugs Pilaralisib (Primary) ; Carboplatin; Paclitaxel
- Indications Advanced breast cancer; Cervical cancer; Colon cancer; Endometrial cancer; Non-small cell lung cancer; Ovarian cancer; Skin cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Sanofi
- 11 Jul 2012 Planned end date changed from 1 Oct 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 06 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
- 20 Sep 2011 Planned end date changed from 1 Sep 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.